Custom Antibody Generation

When the assays you develop are being used to make critical decisions on which therapeutic antibody candidate to advance into the clinic, or are needed to ensure the safety and quality of a biologic during clinical development and manufacturing, you need to be confident in their robustness.

For ligand binding assays (LBAs) such as pharmacokinetic (PK) assays or anti-drug antibody (ADA) assays, the quality of your antibody reagents is critical to your confidence in the performance of your assays. Having highly specific, high affinity and well-characterized antibodies enables development of robust and sensitive assays, leading to data you can rely on.

And, if there is batch-to-batch variability in antibody performance, such as with polyclonal antibodies, you can end up spending a great deal of time in reagent qualification, with no assurance that you’ll have critical quality reagents when you need them.

With custom recombinant monoclonal anti-idiotypic antibody generation from Bio-Rad, you get fast, development of highly specific antibodies that you can rely on throughout the lifecycle of your assay. You also get expert support from a scientific team that has been making recombinant anti-idiotypic antibodies and advancing recombinant antibody production technology¹ for over a decade.

Resources

Webinars

• 

  Transform Your Bioanalytical Assay Development with TrailBlazer Antibodies

  Learn how SpyTag technology has been incorporated with custom recombinant antibody generation to make "TrailBlazer Antibodies".

• 

  Five Ways to Control Your Critical Antibody Reagents and Avoid Bioanalytical Assay Failure

  Learn how to secure high quality, critical antibody reagents early in the development lifecycle, and avoid the frustrations and risks associated with assay development failure.

Documents

• 

  Key Assays to Consider When Testing a Therapeutic Antibody Candidate​

  Developing biotherapeutic antibodies is a complex and lengthy process, but there are key assays to use when testing candidates. We offer some essential advice.

• 

  How to Overcome Challenges in Therapeutic Antibody Discovery

  What to do when your antibody development project fails? We look at how to overcome challenges in therapeutic antibody discovery.

• 

  What to Consider When Choosing a Library for Drug Discovery

  Learn the key differences between library formats (immune, naïve, synthetic, and semi-synthetic) and find out the best source for your next discovery project.

• 

  Methods to Monitor Antibody Immune Responses Against Biotherapeutic Drugs

  Discover how anti-idiotypic antibodies can help overcome the challenges involved in the development of bioanalytical assays to monitor antibody drug candidates.

• 

  A Powerful Approach to Biotherapeutic Discovery

  Phage display libraries offer a powerful approach to biotherapeutic discovery. We explain what they are and the recent developments that you can benefit from.

• 

  Overcome the Challenges of PK Assay Development Using Custom Antibodies

  Learn how the generation of anti-idiotypic antibodies and other high specificity tool antibody critical reagents are made to support PK assay design.

• 

  Rapid Generation of Bispecific Antibodies for High Throughput Screening with SpyLock Technology

  Explore how SpyLock technology streamlines antibody pair prototyping and screening, enabling optimal epitope selection and affinity matching for bispecific antibody development.

References

1. Harth S, Ten Haaf A, Loew C, Frisch C, Knappik A. Generation by phage display and characterization of drug-target complex-specific antibodies for pharmacokinetic analysis of biotherapeutics. mAbs. 2019;11(1):178-190. doi:10.1080/19420862.2018.1538723
2. Mullard A. FDA approves 100th monoclonal antibody product. Nat Rev Drug Discov. 2021;20(7):491-495. doi:10.1038/d41573-021-00079-7